Verastem, Inc. (0LOV.L)
USD 4.46
(-3.44%)
USD 4.46
(-3.44%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 149.71 Million USD | 57.51% |
| 2022 | 95.05 Million USD | -12.53% |
| 2021 | 108.66 Million USD | -29.6% |
| 2020 | 154.34 Million USD | 6.41% |
| 2019 | 145.04 Million USD | -47.68% |
| 2018 | 277.23 Million USD | 208.76% |
| 2017 | 89.79 Million USD | 7.37% |
| 2016 | 83.62 Million USD | -26.05% |
| 2015 | 113.09 Million USD | 14.64% |
| 2014 | 98.64 Million USD | -21.25% |
| 2013 | 125.26 Million USD | 34.8% |
| 2012 | 92.92 Million USD | 57.4% |
| 2011 | 59.03 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 105.74 Million USD | -14.4% |
| 2024 Q1 | 123.53 Million USD | -17.49% |
| 2023 Q3 | 176.15 Million USD | -8.14% |
| 2023 Q1 | 120.87 Million USD | 27.17% |
| 2023 Q2 | 191.75 Million USD | 58.64% |
| 2023 Q4 | 149.71 Million USD | -15.01% |
| 2023 FY | 149.71 Million USD | 57.51% |
| 2022 Q4 | 95.05 Million USD | -14.44% |
| 2022 Q3 | 111.09 Million USD | 10.64% |
| 2022 Q1 | 116.14 Million USD | 6.89% |
| 2022 FY | 95.05 Million USD | -12.53% |
| 2022 Q2 | 100.4 Million USD | -13.55% |
| 2021 Q1 | 136.9 Million USD | -11.3% |
| 2021 FY | 108.66 Million USD | -29.6% |
| 2021 Q3 | 111.87 Million USD | -9.7% |
| 2021 Q4 | 108.66 Million USD | -2.87% |
| 2021 Q2 | 123.89 Million USD | -9.5% |
| 2020 Q4 | 154.34 Million USD | -29.12% |
| 2020 Q3 | 217.77 Million USD | 9.69% |
| 2020 Q1 | 208.15 Million USD | 43.51% |
| 2020 Q2 | 198.53 Million USD | -4.62% |
| 2020 FY | 154.34 Million USD | 6.41% |
| 2019 Q1 | 243.36 Million USD | -12.22% |
| 2019 Q2 | 218.54 Million USD | -10.2% |
| 2019 Q3 | 192.6 Million USD | -11.87% |
| 2019 Q4 | 145.04 Million USD | -24.69% |
| 2019 FY | 145.04 Million USD | -47.68% |
| 2018 Q4 | 277.23 Million USD | 51.37% |
| 2018 Q2 | 172.91 Million USD | 152.76% |
| 2018 Q1 | 68.41 Million USD | -23.81% |
| 2018 FY | 277.23 Million USD | 208.76% |
| 2018 Q3 | 183.15 Million USD | 5.92% |
| 2017 Q3 | 63.13 Million USD | 2.1% |
| 2017 FY | 89.79 Million USD | 7.37% |
| 2017 Q1 | 76.24 Million USD | -8.82% |
| 2017 Q4 | 89.79 Million USD | 42.21% |
| 2017 Q2 | 61.83 Million USD | -18.9% |
| 2016 Q2 | 95.42 Million USD | -6.96% |
| 2016 Q1 | 102.56 Million USD | -9.31% |
| 2016 Q3 | 89.04 Million USD | -6.68% |
| 2016 Q4 | 83.62 Million USD | -6.08% |
| 2016 FY | 83.62 Million USD | -26.05% |
| 2015 Q3 | 123.66 Million USD | -8.87% |
| 2015 FY | 113.09 Million USD | 14.64% |
| 2015 Q2 | 135.69 Million USD | -4.44% |
| 2015 Q4 | 113.09 Million USD | -8.55% |
| 2015 Q1 | 142 Million USD | 43.95% |
| 2014 Q1 | 115.72 Million USD | -7.61% |
| 2014 FY | 98.64 Million USD | -21.25% |
| 2014 Q4 | 98.64 Million USD | 0.78% |
| 2014 Q3 | 97.88 Million USD | -8.81% |
| 2014 Q2 | 107.34 Million USD | -7.24% |
| 2013 Q4 | 125.26 Million USD | -5.41% |
| 2013 FY | 125.26 Million USD | 34.8% |
| 2013 Q1 | 86.24 Million USD | -7.19% |
| 2013 Q2 | 79.96 Million USD | -7.28% |
| 2013 Q3 | 132.42 Million USD | 65.62% |
| 2012 Q1 | 110.7 Million USD | 87.52% |
| 2012 Q3 | 98.83 Million USD | -6.47% |
| 2012 Q4 | 92.92 Million USD | -5.98% |
| 2012 FY | 92.92 Million USD | 57.4% |
| 2012 Q2 | 105.66 Million USD | -4.55% |
| 2011 FY | 59.03 Million USD | 0.0% |
| 2011 Q4 | 59.03 Million USD | -5.94% |
| 2011 Q3 | 62.76 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 70.006% |
| Dynavax Technologies Corporation | 997.09 Million USD | 84.985% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 89.374% |
| Perrigo Company plc | 10.8 Billion USD | 98.615% |
| Illumina, Inc. | 10.11 Billion USD | 98.519% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.848% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 80.814% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.815% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.439% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 32.713% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.547% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -127.916% |
| Waters Corporation | 4.62 Billion USD | 96.764% |
| Biogen Inc. | 26.84 Billion USD | 99.442% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 9.437% |
| Evolus, Inc. | 188.99 Million USD | 20.783% |
| Adicet Bio, Inc. | 207.29 Million USD | 27.775% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -18.971% |
| bluebird bio, Inc. | 619.16 Million USD | 75.819% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 27.249% |
| FibroGen, Inc. | 423.52 Million USD | 64.65% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.609% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -429.555% |
| Homology Medicines, Inc. | 47.05 Million USD | -218.163% |
| Geron Corporation | 394.07 Million USD | 62.008% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 96.091% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 80.753% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 87.51% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 59.37% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 88.492% |
| Zoetis Inc. | 14.28 Billion USD | 98.952% |
| Abeona Therapeutics Inc. | 64 Million USD | -133.927% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 95.538% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 97.812% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.341% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -167.597% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 94.993% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 9.538% |
| Nektar Therapeutics | 398.03 Million USD | 62.386% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 74.548% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 24.157% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 95.414% |
| OPKO Health, Inc. | 2.01 Billion USD | 92.558% |
| Exelixis, Inc. | 2.94 Billion USD | 94.912% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 95.395% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 75.911% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 3.024% |
| uniQure N.V. | 831.68 Million USD | 81.998% |
| Imunon, Inc. | 21.91 Million USD | -583.08% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 85.731% |
| Insmed Incorporated | 1.32 Billion USD | 88.742% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 91.362% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 84.024% |
| TG Therapeutics, Inc. | 329.58 Million USD | 54.574% |
| Incyte Corporation | 6.78 Billion USD | 97.792% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 91.841% |